Peer-reviewedCC BYJAAD international
Deucravacitinib versus placebo in adults with moderate-to-severe hidradenitis suppurativa: A pilot study.
- 1Clinical Laboratory for Epidemiology and Applied Research in Skin (CLEARS), Department of Dermatology, Beth Israel Deaconess Medical Center, Boston, Massachusetts.
- 2Harvard Medical School, Boston, Massachusetts.
- 3Department of Medicine, Santa Barbara Cottage Hospital, Santa Barbara, California.
Related
- Efferocytosis-Related Transcriptional Dysregulation in Hidradenitis Suppurativa Lesional Macrophages: A Multi-Cohort Single-Cell and Bulk Transcriptomic Study
- Male-predominant, perianal-prone hidradenitis suppurativa in China: A cohort study of 614 patients.
- Real-world patient journey and unmet needs of people with hidradenitis suppurativa: Social media research in China.
- Geospatial Associations of Hidradenitis Suppurativa With Structurally Related Airborne Toxins
- Emotional and social burden of hidradenitis suppurativa: a qualitative multi-centre narrative medicine project in Italy
BibTeX
@article{porter2026deucravacitinib,
title = {{Deucravacitinib versus placebo in adults with moderate-to-severe hidradenitis suppurativa: A pilot study.}},
author = {Martina L Porter and Maneli Doroudian Tehrani and Nazrin Ashina and Bruna G O Wafae and Thao-Mary Tran and Hoang Truong and William Sweet and Julia L Gao and Prerna Salian and Alexa B Kimball},
journal = {JAAD international},
year = {2026},
month = sep,
doi = {10.1016/j.jdin.2026.08.009},
url = {https://europepmc.org/article/MED/42898106},
note = {CC BY},
}
RIS
TY - JOUR
TI - Deucravacitinib versus placebo in adults with moderate-to-severe hidradenitis suppurativa: A pilot study.
AU - Martina L Porter
AU - Maneli Doroudian Tehrani
AU - Nazrin Ashina
AU - Bruna G O Wafae
AU - Thao-Mary Tran
AU - Hoang Truong
AU - William Sweet
AU - Julia L Gao
AU - Prerna Salian
AU - Alexa B Kimball
PY - 2026
DA - 2026/09/03
JO - JAAD international
DO - 10.1016/j.jdin.2026.08.009
UR - https://europepmc.org/article/MED/42898106
SN - 2666-3287
ER -